norbert w bischofberger phd  gilead norbert w bischofberger phd home  about  senior management  norbert w bischofberger phd senior management john f milligan phd john c martin phd gregg h alton norbert w bischofberger phd andrew cheng md phd william a lee phd john mchutchison md jim meyers brett pletcher martin b silverstein md robin l washington katie l watson taiyin yang phd kevin young cbe board of directors the information in this section is intended for visitors outside the united states continue norbert w bischofberger phd executive vice president research and development and chief scientific officer dr bischofberger joined gilead sciences in  and has served as executive vice president for research and development since  and chief scientific officer since  prior to joining gilead dr bischofberger was a senior scientist in genentech’s dna synthesis group from  until  dr bischofberger received a phd in organic chemistry from zurich’s eidgenössische technische hochschule and performed postdoctoral research in steroid chemistry at syntex he also performed additional research in organic chemistry and applied enzymology in professor george whiteside’s lab at harvard university in cambridge massachusetts dr norbert w bischofberger  bayer menucontactsharesearchde homeinvestorsannual stockholders’ meeting notice of the meeting  agendaitem  overview bayer group about bayer key figures profile and organization subsidiaries acquisitions and divestitures our products markets and economic outlook research  development bayersocial media brochure names figures facts mission  values strategic alignment group strategy business strategies valuebased performance outlook and targets opportunity and risk report corporate governance articles of incorporation board of management supervisory board sustainability and commitment stock investors key messages to investors new investors institutional investors private investors fixed income investors socially responsible investing listing and key figures basic data key figures share listings equity indices adr program share price current share price charts closing prices dividends profitability analysts analysts ratings consensus stockholders portal ownership structure overview voting rights announcements archive voting rights announcements stock programs overview aspire participation program stock history glossary archive bonds overview financial strategy financial management liability mix maturity profile net financial debt credit default swaps funding instruments overview debt issuance programme commercial paper programme syndicated loan facility bonds issued rating bond news credit analysts credit relations reports annual reports overview key figures comparison financial position income statement cashflow statement segment overview region overview fiveyear summary quarterly reports bayer ag financial statements sustainability reports archive annual stockholders’ meeting  overview notice of the meeting  agenda overview item  item  item  item  item  item  item  stockholders countermotions and election proposals how to vote  stockholders’ portal voting results service overview important dates getting to the meeting stockholders’ hotline downloads archive events calendar live events q  conference call q  conference call meet management  in london fyq  conference call bayer to acquire monsanto investor conferences stockholders meeting overview asm  asm  asm  asm  asm  asm  asm  asm  asm  asm  asm  asm  extraordinary asm  asm  asm  asm  press conferences roadshows other presentations archive  overview q  conference call meet management  bayer to acquire monsanto q  conference call bayer offers to acquire monsanto q  conference call fyq  conference call  overview q  conference call finerenone data at esc congress  q  conference call meet management  ny q  conference call meet management  in berlin fyq  conference call  overview q  conference call meet management  ldn conference call  planned demerger materialscience q  conference call meet management  ny conference call  acquisition cc business merck q  conference call meet management  lev fyq  conference call  overview q  conference call meet management  ldn q  conference call meet management  ny q  conference call meet management  lev fyq  conference call  overview meet management in tokyo q  conference call riociguat data at chest  q  conference call meet management  ny q  conference call conference call acc  meet management  lev fyq  conference call regorafenib data at ascogi  overview china investor conference rivaroxaban data at aha  q  conference call q  conference call q  conference call rivaroxaban data at acc  fyq  conference call  overview q  conference call rivaroxaban data at esc  q  conference call q  conference call fyq  conference call  overview rivaroxaban data at ash  q  conference call q  conference call riociguat data at ats  q  conference call fyq  conference call  overview rivaroxaban data at aha  q  conference call q  conference call rivaroxaban data at efort  q  conference call fyq  conference call  overview rivaroxaban data at ash  q  conference call q  conference call healthcare investor day  nexavar data at asco  q  conference call fyq  conference call  overview nexavar melanoma conference call q  conference call rivaroxaban conference call q  conference call q  conference call fyq  conference call  overview bayer rd investor day  q  conference call csfb chemical hybrid tour  cropscience analyst  investor days q  conference call data on bay  at isth  sorafenib data at asco  q  conference call spring investor conference   overview fall investor conference  bay  data at eortc symposium csfb field trip on september   h  investor conference bay  data at asco  q  conference call spring investor conference   overview csfb field trip on november   fall investor conference  conference call on adhoc message nov   q  conference call spring investor conference   overview spring investor conference  half year investor conference  spring investor conference  spring financial news conference   overview fall investor conference  investor conference call on the acquisition of aventis cropscience news conference call acquisition of aventis cropscience half year investor conference  spring investor conference  spring financial news conference   overview fall investor conference  investor conference new york spring investor conference  spring press conference   inside information latest inside information archive overview adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  adhoc  news investor news press archive overview investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  investor news  handouts investor handout investor factsheet presentations archive investor handouts archive presentations downloads current downloads                        service contact ir team order publications newsletter rss newsfeeds rss help page podcasts mobile services smsservice collected downloads new on this site faqs investor factsheet   annual stockholders’ meeting  dr norbert w bischofberger executive vice president research  development and chief scientific officer of gilead sciences inc january   born in mellau austria  –  studies of chemistry at leopoldfranzensuniversity innsbruck austria  –  doctorate dr rer nat at the eidgenössische technische hochschule zurich switzerland  –  postdoc at syntex inc palo alto california usa  –  postdoc at harvard university cambridge massachusetts usa  –  scientist in the molecular biology department at genentech inc south san francisco california usa from  manager dna synthesis since  gilead sciences inc foster city california usa  –  director organic chemistry  –  vice president organic chemistry  –  vice president research  –  senior vice president research  –  senior vice president research and development since  executive vice president research  development and chief scientific officer membership of statutory supervisory boards none membership of comparable control bodies of corporations in germany or abroad incarda therapeutics inc brisbane california usa member of the board of directors since  close× gild norbert w bischofberger insider trades for gilead sciences inc bulletin investor alert tokyo markets close in currencies europe markets london markets expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close gilead sciences inc nasdaq gild go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus gilead sciences inc after hours  quotes are delayed by  min jul    pm gild quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual norbert w bischofberger dr norbert w bischofberger is chief scientific officer  executive vpresearch at gilead sciences inc dr bischofberger was previously employed as senior scientistdna synthesis group by genentech inc he received his undergraduate degree from the university of innsbruck and a doctorate degree from the swiss federal institute of technology transactions date shares transaction value     gift at  per share      gift at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      award at  per share      gift at  per share      gift at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      award at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      disposition at  per share      award at  per share      disposition at  per share      award at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      derivativenonderivative trans at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      disposition at  per share      derivativenonderivative trans at  per share      disposition at  per share      derivativenonderivative trans at  per share      gift at  per share      award at  per share      award at  per share      gift at  per share      award at  per share      gift at  per share      award at  per share      gift at  per share      award at  per share      gift at  per share      derivativenonderivative trans at  per share      award at  per share      award at  per share      gift at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr john c martin executive chairman dr john f milligan president chief executive officer  director mr kevin b young chief operating officer ms robin l washington chief financial officer  executive vice president mr gregg h alton executive vpcorporate  medical affairs dr william a lee executive vice presidentresearch dr norbert w bischofberger chief scientific officer  executive vpresearch dr andrew cheng executive vpclinical research  development dr john g mchutchison executive vice presidentclinical research dr alessandro riva senior vphematology  oncology therapeutic mr brett a pletcher secretary chief compliance officer  executive vp mr james r meyers executive vpworldwide commercial operations dr martin j silverstein executive vice presidentstrategy dr taiyin yang evppharmaceutical development  manufacturing dr george pratt shultz directoremeritus ms katie l watson executive vice presidenthuman resources ms kelly a kramer independent director dr john francis cogan lead independent director mr per woldolsen independent director mr kevin e lofton independent director mr nicholas g moore independent director dr richard j whitley independent director ms gayle edlund wilson independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo open marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pat least  dead after overheated tractortrailer found outside texas walmart p‘full transparency’ doesn’t mean what scaramucci apparently thinks it means pstocks brace for volatility in earnings deluge fed meeting looms pthe dark side of cruises pif you suddenly quit your job like sean spicer here’s what you should do next pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pnever ever say these things to a coworker pmy uncle with dementia needs longterm care — should i refinance his house pthis is the deadliest time of your life to put on weight p easily avoidable reasons why millennials can’t have nice things or save any money pwhy house prices in gay neighborhoods are soaring pnearly  of adults don’t have life insurance — these startups are trying to change that pmarie kondo says this one thing could be holding you back from falling in love pthis luxury credit card is only for truly big spenders phow elon musk and shorter commutes could transform people’s lives pbanks have raised creditcard interest rates — but not savings account rates pthe most expensive city in the world is not new york or san francisco p in  americans say they will die in debt pshopping at costco and  other things that prove rich people are cheap aheavy showers swamp new orleans street with rainwater loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  bischofberger norbert w top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active bischofberger norbert w • foster city ca how do i update this listing bischofberger norbert w is based out of foster city whalewisdom has at least  insider transactions form  in our database for bischofberger norbert w summary dg insider form  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from bischofberger norbert w enter your email address below and choose submit your email cancel contact info bischofberger norbert w  lakeside dr foster city ca     business phone  sec sic codebiological products no disgnostic substances recent sec filings  filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on   filed on  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading elevate your investments try it for free norbert bischofberger  wikipedia norbert bischofberger from wikipedia the free encyclopedia jump to navigation search external video norbert bischofberger  others the evolution of hivaids therapies a conversation  chemical heritage foundation dr norbert bischofberger born  january  in mellau austria is an austrian scientist and one of the inventors of the antiviral drug tamiflu generically known as oseltamivir which is as of  the only oral medication on the market to treat influenza a and b as well as the  pandemic hn swine flu the spread of which caused an ongoing pandemic in  bischofberger is currently the executive vice president research and development and chief scientific officer at gilead sciences a biopharmaceutical company specializing in antivirals contents  education  tamiflu  references  external links educationedit bischofberger has received a bachelor of science in chemistry from the university of innsbruck a phd in organic chemistry at the eth zurich a science and technology university in zurich and has done postdoctoral work at harvard university tamifluedit he worked as part of the dna synthesis group at genentech from – before joining gilead in  as director of organic chemistry in  he began work as head of a team to create tamiflu in  clinical studies were carried out on the drug which was the first orally active commercially developed antiinfluenza medication explaining the motivation behind this he said we decided to create a pill and not a medication to inhale because especially people who suffer from influenza struggle with breathing difficulties and the agent would only reach the lung three years later the right to market and develop tamiflu were sold to roche with bischofberger and gilead retaining the intellectual rights to it bischofberger has publicly displayed pessimism over the risk viruses pose saying i think the threat by new bacterial or viral agents is higher than the potential of a nuclear war referencesedit  a b allan hall  inventor of tamiflu profits from swine flu pandemic the daily telegraph retrieved    norbert w bischofberger forbes retrieved    thomas hochwarter  scientist who invented ´tamiflu´ predicts dark times austrian times retrieved    a b blessing in disguise for tamiflu inventor malay mail  retrieved   external linksedit forbescom profile retrieved from httpsenwikipediaorgwindexphptitlenorbertbischofbergeroldid categories austrian scientistsaustrian chemistsorganic chemistsaustrian pharmacologistsliving people births navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view norbert bischofberger  wikipedia norbert bischofberger from wikipedia the free encyclopedia jump to navigation search external video norbert bischofberger  others the evolution of hivaids therapies a conversation  chemical heritage foundation dr norbert bischofberger born  january  in mellau austria is an austrian scientist and one of the inventors of the antiviral drug tamiflu generically known as oseltamivir which is as of  the only oral medication on the market to treat influenza a and b as well as the  pandemic hn swine flu the spread of which caused an ongoing pandemic in  bischofberger is currently the executive vice president research and development and chief scientific officer at gilead sciences a biopharmaceutical company specializing in antivirals contents  education  tamiflu  references  external links educationedit bischofberger has received a bachelor of science in chemistry from the university of innsbruck a phd in organic chemistry at the eth zurich a science and technology university in zurich and has done postdoctoral work at harvard university tamifluedit he worked as part of the dna synthesis group at genentech from – before joining gilead in  as director of organic chemistry in  he began work as head of a team to create tamiflu in  clinical studies were carried out on the drug which was the first orally active commercially developed antiinfluenza medication explaining the motivation behind this he said we decided to create a pill and not a medication to inhale because especially people who suffer from influenza struggle with breathing difficulties and the agent would only reach the lung three years later the right to market and develop tamiflu were sold to roche with bischofberger and gilead retaining the intellectual rights to it bischofberger has publicly displayed pessimism over the risk viruses pose saying i think the threat by new bacterial or viral agents is higher than the potential of a nuclear war referencesedit  a b allan hall  inventor of tamiflu profits from swine flu pandemic the daily telegraph retrieved    norbert w bischofberger forbes retrieved    thomas hochwarter  scientist who invented ´tamiflu´ predicts dark times austrian times retrieved    a b blessing in disguise for tamiflu inventor malay mail  retrieved   external linksedit forbescom profile retrieved from httpsenwikipediaorgwindexphptitlenorbertbischofbergeroldid categories austrian scientistsaustrian chemistsorganic chemistsaustrian pharmacologistsliving people births navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view norbert bischofberger  wikipedia norbert bischofberger from wikipedia the free encyclopedia jump to navigation search external video norbert bischofberger  others the evolution of hivaids therapies a conversation  chemical heritage foundation dr norbert bischofberger born  january  in mellau austria is an austrian scientist and one of the inventors of the antiviral drug tamiflu generically known as oseltamivir which is as of  the only oral medication on the market to treat influenza a and b as well as the  pandemic hn swine flu the spread of which caused an ongoing pandemic in  bischofberger is currently the executive vice president research and development and chief scientific officer at gilead sciences a biopharmaceutical company specializing in antivirals contents  education  tamiflu  references  external links educationedit bischofberger has received a bachelor of science in chemistry from the university of innsbruck a phd in organic chemistry at the eth zurich a science and technology university in zurich and has done postdoctoral work at harvard university tamifluedit he worked as part of the dna synthesis group at genentech from – before joining gilead in  as director of organic chemistry in  he began work as head of a team to create tamiflu in  clinical studies were carried out on the drug which was the first orally active commercially developed antiinfluenza medication explaining the motivation behind this he said we decided to create a pill and not a medication to inhale because especially people who suffer from influenza struggle with breathing difficulties and the agent would only reach the lung three years later the right to market and develop tamiflu were sold to roche with bischofberger and gilead retaining the intellectual rights to it bischofberger has publicly displayed pessimism over the risk viruses pose saying i think the threat by new bacterial or viral agents is higher than the potential of a nuclear war referencesedit  a b allan hall  inventor of tamiflu profits from swine flu pandemic the daily telegraph retrieved    norbert w bischofberger forbes retrieved    thomas hochwarter  scientist who invented ´tamiflu´ predicts dark times austrian times retrieved    a b blessing in disguise for tamiflu inventor malay mail  retrieved   external linksedit forbescom profile retrieved from httpsenwikipediaorgwindexphptitlenorbertbischofbergeroldid categories austrian scientistsaustrian chemistsorganic chemistsaustrian pharmacologistsliving people births navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page printexport create a bookdownload as pdfprintable version languages deutsch edit links this page was last edited on  june  at  text is available under the creative commons attributionsharealike license additional terms may apply by using this site you agree to the terms of use and privacy policy wikipedia® is a registered trademark of the wikimedia foundation inc a nonprofit organization privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view norbert w bischofberger gilead sciences inc chief scientific officer  evp research  development  redbooks brands marketers agencies search less sell more    sign in get a free trial    contact us   norbert w bischofberger chief scientific officer  evp research  development gilead sciences inc realtime sales trigger feed  generated by redbooks machine learning and natural language processing technology tracking  news sources to aggregate all new executives jobrole changes and news on decision makers brands and agencies in the mediamarketing industry this sales feed is for norbert w bischofberger at gilead sciences inc norbert w bischofberger works as chief scientific officer  evp research  development  acting in a dataprivacy role  gilead sciences inc is a leader in pharmaceuticals  health care products  redbooks tracks personnel changes for advertisers spending over  million annually for more dataprivacy leads or mediamarketing prospecting automation start a free trial now recent related news  ema validates gilead sciences marketing application for bicftctaf combination  during the phase iii clinical trials bicftctaf has shown high rates of virologic suppression and no treatmentemergent resistance through  weeks among treatmentnave adult patients as well as virologically suppressed adult patients who switched regimens gilead sciences chief scientific officer and research and development executive vicepresident dr norbert bischofberger said this investigational single tablet regimen represents a potential advancement in hiv treatment by combining the potency of an integrase inhibitor bictegravir with the demonstrated safety profile of the ftctaf backbone gilead remains at the forefront of driving innovation in hiv with our continued commitment to working to simplify and improve treatments for people living with hiv people in this article norbert w bischofberger  gilead submits new drug application to us food and drug administration for fixeddose combination of bictegravir emtricitabine  bicftctaf has demonstrated high rates of virologic suppression and no treatmentemergent resistance through  weeks in phase  clinical trials among treatmentnaive adult patients and among virologically suppressed adult patients who switched regimens see also drugs and therapies  antiretrovirals we aim to simplify the management of hiv for a broad range of patients with this single tablet regimen that combines the potency of an integrase inhibitor bictegravir and the demonstrated longterm safety profile of the ftctaf backbone said norbert bischofberger phd executive vice president research and development and chief scientific officer gilead sciences this regulatory filing is a demonstration of gileads ongoing commitment to bringing forward treatment innovations that have the potential to address the needs of patients and physicians people in this article norbert w bischofberger learn more about norbert w bischofberger and  key contacts   create targeted lead lists   gain insider knowledge with advanced machine  learning   realtime verified contact info enter work email please enter email address please enter valid email address learn more about norbert w bischofberger and  key contacts first name  please enter first name last name  please enter last name company name  please enter company name email  phone  please enter phone number please enter  digits number what industry are you in    please select one the categories below please enter value for the industry  media sales  production  adtechmartech  sponsorship sales   agency new business   other what is your role    please select one the categories below please enter value for the role   csuite   vpmanager   sales rep   other thank you for registering for a free redbookscom trial we are processing your request and will be in touch shortly to get you started for immediate assistance please call us at   or email us at inforedbookscom home learn more free trial features ad think events thought leadership events top advertiser directory top agency directory add your agency update your agency agency showcase advertising associations creative spotlight services and suppliers about us blog contact us jobs terms  conditions privacy policy customer support   connect with us copyright   red books llc all rights reserved norbert w bischofberger of gilead sciences inc executive profile   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center gilead sciences inc  gild add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  norbert w bischofberger norbert w bischofberger executive vice president research and development and chief scientific officer profile connections biography norbert w bischofberger phd age  is our executive vice president research and development and chief scientific officer dr bischofberger joined gilead in  and has served as executive vice president research and development since  and chief scientific officer since  prior to joining gilead dr bischofberger was a senior scientist in genentech incs dna synthesis group from  to  he received his phd in organic chemistry at the eidgenossische technische hochschule eth in zurich switzerland and performed postdoctoral research in steroid chemistry at syntex he also performed additional research in organic chemistry and applied enzymology in professor george whitesides lab at harvard university in cambridge massachusetts board membership norbert w bischofberger is not a member of any boards   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed   gilead senior management senior management home  about  senior management senior management john f milligan phd john c martin phd gregg h alton norbert w bischofberger phd andrew cheng md phd william a lee phd john mchutchison md jim meyers brett pletcher martin b silverstein md robin l washington katie l watson taiyin yang phd kevin young cbe board of directors share the information in this section is intended for visitors outside the united states continue john f milligan phd    president and chief executive officer john c martin phd    executive chairman gregg h alton    executive vice president corporate and medical affairs norbert w bischofberger phd    executive vice president research and development and chief scientific officer andrew cheng md phd    executive vice president clinical research and development operations william a lee phd    executive vice president research john mchutchison md    executive vice president clinical research jim meyers    executive vice president commercial operations brett a pletcher    executive vice president general counsel and chief compliance officer martin b silverstein md    executive vice president strategy robin l washington    executive vice president and chief financial officer katie l watson    executive vice president human resources taiyin yang phd    executive vice president pharmaceutical development and manufacturing kevin young cbe    chief operating officer norbert bischofberger executive vice president gilead sciences timesjavascript is disabled market profiles login sign up login sign up   edit person norbert bischofberger executive vice president at gilead sciences location foster city ca add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop norbert bischofberger executive vice president at gilead sciences location foster city ca add to my lists claim share copy the following code on your pageblog suggested widget size mobile desktop norbert w bischofberger phd executive vice president research and development and chief scientific officer norbert w bischofberger phd executive vice president research and development and chief scientific officer dr bischofberger joined gilead sciences in  and has served executive vice president for research and development since  and chief scientific officer since  prior to joining gilead dr bischofberger was a senior scientist in genentech’s dna synthesis group from  until  dr bischofberger received a phd in organic chemistry from zurich’s eidgenossische technische hochshule and performed postdoctoral research in steroid chemistry at syntex he also performed ad…  companies in career na related markets  colleagues na related investments alias norbert bischofberge norbert bishofberger industry biological product except diagnostic manufacturing tags na topics of influence antiretroviral drug na na careers achievements investments related people edit view all norbert bischofbergercareer   gilead sciences executive vice president  to  genentech’s dna synthesis group senior scientist competencies edit view all norbert bischofbergereducation  a science and technology university organic chemistry university of innsbruck chemistry edit norbert bischofbergerachievements and recognitions add milestone no milestones has been recorded for norbert bischofberger edit norbert bischofbergerlinks add link no links has been recorded for norbert bischofberger norbert bischofbergerinvestmentsacquisitions no investments has been recorded for norbert bischofberger norbert bischofbergerinvestments representing others no investment reps has been recorded for norbert bischofberger norbert bischofbergerrelated people colleagues at gilead sciences alessandro riva senior vice president of hematology and oncology therapeutic area head jan taiyin yang evp pharmaceutical development and manufacturing  andrew cheng evp hiv therapeutics and development operations jan philippe bishop sr vice president hematologyoncology dec view all norbert bischofbergerrecommended market profiles  telemedicine  or more employees  companies social media marketing chiefmarteccom    employees  companies big data universe list of lists  or more employees  companies aggregated marketing technology  or more employees  companies shared economy landscape jeremiah owyang  or more employees  companies inside sales landscape  or more employees  companies